One-year data from a large real-world dataset provide reassurance that clinical outcomes with the new-generation LAA occlusion device for stroke prevention compare well with those from pivotal trials.
SURPASS Study Confirms Real-World Safety and Efficacy of Watchman FLX Through 45 Days
Interim data from a large real-world dataset provide reassurance about acute and subacute procedural outcomes with the new-generation LAA occlusion device for stroke prevention.
Insights From 1,000+ Left Atrial Appendage Closure Procedures With Watchman
Our world-leading experience in this procedure confirms that it reduces stroke risk in high-risk patients and can be safely combined with TAVR as well as atrial fibrillation ablation.
Left Atrial Appendage Closure Device Found Safe and Effective for AF Despite Prior ICH
Patients with a history of intracranial hemorrhage have had few safe treatment options for nonvalvular atrial fibrillation. A new study of the Watchman device suggests that may be changing.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Watchman in the Real World: Reports on Use in High-Risk Patients and Overall Safety
Findings from three Cleveland Clinic real-world studies suggest a wider range of patients stand to benefit from the left atrial appendage closure device.
LAA Closure Device a Reality: Now What? (Video)
The newly approved WATCHMAN™ device can prevent stroke in high-risk patients with nonvalvular atrial fibrillation. But when exactly is left atrial appendage closure preferable to warfarin therapy?